Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...
Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...
Zacks Investment Research on MSN
RMD stock set to gain from FDA clearance of AI-enabled smart comfort
Resmed RMD has received FDA clearance for Personalized Therapy Comfort Settings (“PTCS”), which will be marketed as Smart Comfort. The company will debut Smart Comfort in early 2026 in a limited U.S.
Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...
Personal Therapy Assistant feature for AirSense 11 users, seen here within the myAir app SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ResMed, a global leader in digital health and sleep apnea ...
SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced ...
New study confirms that engaging patients with digital self-monitoring in their treatment through myAir improves adherence ResMed today announced new European research from Price Waterhouse Coopers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback